Navigation Links
New research suggests common anti-seizure medications may increase risk of cardiovascular problems
Date:3/18/2009

PHILADELPHIA An important clinical repercussion in the treatment of epilepsy has been discovered by a research team led by Scott Mintzer, M.D., assistant professor in the Department of Neurology and the Jefferson Comprehensive Epilepsy Center at Jefferson Medical College of Thomas Jefferson University. The team has determined that two of the most commonly prescribed anti-seizure medications may lead to significantly increased levels of cholesterol, C-reactive protein and other markers of cardiovascular disease risk. The finding set to be published in the March 18th online edition of Annals of Neurology may help doctors manage the care of patients with seizures more effectively by prescribing different anti-seizure medications that will not adversely affect cardiovascular health.

The study involved two of the most widely-prescribed anticonvulsants phenytoin (Dilantin) and carbamazepine (Tegretol, Carbatrol) which have potent effects on many enzymes in the body involved in different areas of metabolism. The researchers recruited 34 epilepsy patients taking either one of those two drugs who were being switched over to one of two newer anti-seizure drugs which do not widely affect enzymes lamotrigine (Lamictal) or levetiracetam (Keppra). The goal was to determine if the change affected the patients' cholesterol levels and other key markers of cardiovascular disease.

Just 6 weeks after the patients' drugs were switched, there were significant declines in total cholesterol, non-high-density lipoprotein (commonly referred to as 'bad') cholesterol, triglycerides and C-reactive protein, suggesting the older, commonly-used drugs might substantially increase the risk of cardiovascular disease.

"The epilepsy patients in this study saw a rapid and clinically significant improvement in several markers related to cardiovascular disease, including a decrease in total cholesterol that averaged 26 points. This is almost certainly not due to some positive effect from the new drugs. It's a consequence of being taken off the older ones, which were causing the cholesterol and other markers to be elevated in the first place," said Dr. Mintzer. "While more investigation is needed, these results may help physicians better understand the risks of these drugs and choose the most appropriate treatment for their epilepsy patients, especially those who are already at risk for cardiovascular disease or have a family history of it."

According to the Epilepsy Foundation, which also funded this study, there are almost three million people living with epilepsy with an additional 200,000 new diagnoses being made each year. Dilantin is the most commonly prescribed anticonvulsant in this country, and has been since its discovery in 1938. Throughout the industrialized world, Tegretol has been the most commonly prescribed anticonvulsant for more than 20 years. The results of this study could have far-reaching effects on how the millions of current, and future patients are, or will be, treated.


'/>"/>

Contact: Ed Federico
ed.federico@jefferson.edu
215-955-5507
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Researcher wins $2.6 million grant for depression care study
2. Frost and Sullivan Picks Epinex for Diabetes Research Award
3. Foundation for Biomedical Research Releases Groundbreaking PSA
4. Fish health claims may cause more environmental harm than good: UBC-St. Michaels researchers
5. IADR Oral Medicine and Pathology Research Award presented to UCLA professor
6. Researchers clone key sperm-binding proteins
7. Collagen injections can help some incontinence patients when surgery fails, researcher finds
8. Research Finds Popular Household Pets Transmit Dangerous Parasites to Humans
9. Researchers find sustained improvement in health in Experience Corps tutors over 55
10. Researchers develop DNA patch for canine form of muscular dystrophy
11. University of Notre Dame Chooses Latest Technology From Carestream Molecular Imaging For Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: